Author:
Chanprapaph Kumutnart,Rutnin Suthinee,Vachiramon Vasanop
Publisher
Springer Science and Business Media LLC
Subject
Dermatology,General Medicine
Reference103 articles.
1. Peuvrel L, Dreno B. Dermatological toxicity associated with targeted therapies in cancer: optimal management. Am J Clin Dermatol. 2014;15(5):425–44.
2. Gomez P, Lacouture ME. Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer. Oncologist. 2011;16(11):1508–19.
3. Zimmerman EI, Gibson AA, Hu S, Vasilyeva A, Orwick SJ, Du G, et al. Multikinase inhibitors induce cutaneous toxicity through OAT6-mediated uptake and MAP3K7-driven cell death. Cancer Res. 2016;76(1):117–26.
4. Common Terminology Criteria for Adverse Events (CTCAE) v4.03. US Department of Health and Human Services. National Institute of Health. National Cancer Institute. May 28, 2009. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-0614_QuickReference_5x7.pdf . Accessed 1 Feb 2016
5. Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther. 2005;315(3):971–9.
Cited by
37 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献